Report cover image

Global Opioid Receptor Agonist Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 198 Pages
SKU # APRC20355710

Description

Summary

According to APO Research, The global Opioid Receptor Agonist market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Opioid Receptor Agonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Opioid Receptor Agonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Opioid Receptor Agonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Opioid Receptor Agonist is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Opioid Receptor Agonist include Allergan, DAIICHI SANKYO COMPANY, Endo Pharmaceuticals, Fresenius Kabi, Hikma Pharmaceuticals, Indivior, Mylan N.V., Piramal Critical Care and Purdue Pharma, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Opioid Receptor Agonist, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Opioid Receptor Agonist, also provides the sales of main regions and countries. Of the upcoming market potential for Opioid Receptor Agonist, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Opioid Receptor Agonist sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Opioid Receptor Agonist market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Opioid Receptor Agonist sales, projected growth trends, production technology, application and end-user industry.

Opioid Receptor Agonist Segment by Company

Allergan
DAIICHI SANKYO COMPANY
Endo Pharmaceuticals
Fresenius Kabi
Hikma Pharmaceuticals
Indivior
Mylan N.V.
Piramal Critical Care
Purdue Pharma
Sun Pharmaceutical Industries
Tris Pharma
US WorldMeds
Pfizer
Johnson & Johnson
Teva Pharmaceutical Industries
Opioid Receptor Agonist Segment by Type

Morphine
Codeine
Fentanyl
Others
Opioid Receptor Agonist Segment by Application

Retail Pharmacy
Online Pharmacy
Hospital Pharmacy
Opioid Receptor Agonist Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid Receptor Agonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Opioid Receptor Agonist and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid Receptor Agonist.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioid Receptor Agonist market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Opioid Receptor Agonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Opioid Receptor Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Opioid Receptor Agonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report

Table of Contents

198 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Opioid Receptor Agonist Market Size, 2020 VS 2024 VS 2031
1.3 Global Opioid Receptor Agonist Market Size Estimates and Forecasts (2020-2031)
1.4 Global Opioid Receptor Agonist Sales Estimates and Forecasts (2020-2031)
1.5 Global Opioid Receptor Agonist Market Average Price (2020-2031)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Opioid Receptor Agonist Market Dynamics
2.1 Opioid Receptor Agonist Industry Trends
2.2 Opioid Receptor Agonist Industry Drivers
2.3 Opioid Receptor Agonist Industry Opportunities and Challenges
2.4 Opioid Receptor Agonist Industry Restraints
3 Opioid Receptor Agonist Market by Manufacturers
3.1 Global Opioid Receptor Agonist Revenue by Manufacturers (2020-2025)
3.2 Global Opioid Receptor Agonist Sales by Manufacturers (2020-2025)
3.3 Global Opioid Receptor Agonist Average Sales Price by Manufacturers (2020-2025)
3.4 Global Opioid Receptor Agonist Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
3.5 Global Opioid Receptor Agonist Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Opioid Receptor Agonist Manufacturers, Product Type & Application
3.7 Global Opioid Receptor Agonist Manufacturers Establishment Date
3.8 Market Competitive Analysis
3.8.1 Global Opioid Receptor Agonist Market CR5 and HHI
3.8.2 Global Top 5 and 10 Opioid Receptor Agonist Players Market Share by Revenue in 2024
3.8.3 2024 Opioid Receptor Agonist Tier 1, Tier 2, and Tier 3
4 Opioid Receptor Agonist Market by Type
4.1 Opioid Receptor Agonist Type Introduction
4.1.1 Morphine
4.1.2 Codeine
4.1.3 Fentanyl
4.1.4 Others
4.2 Global Opioid Receptor Agonist Sales by Type
4.2.1 Global Opioid Receptor Agonist Sales by Type (2020 VS 2024 VS 2031)
4.2.2 Global Opioid Receptor Agonist Sales by Type (2020-2031)
4.2.3 Global Opioid Receptor Agonist Sales Market Share by Type (2020-2031)
4.3 Global Opioid Receptor Agonist Revenue by Type
4.3.1 Global Opioid Receptor Agonist Revenue by Type (2020 VS 2024 VS 2031)
4.3.2 Global Opioid Receptor Agonist Revenue by Type (2020-2031)
4.3.3 Global Opioid Receptor Agonist Revenue Market Share by Type (2020-2031)
5 Opioid Receptor Agonist Market by Application
5.1 Opioid Receptor Agonist Application Introduction
5.1.1 Retail Pharmacy
5.1.2 Online Pharmacy
5.1.3 Hospital Pharmacy
5.2 Global Opioid Receptor Agonist Sales by Application
5.2.1 Global Opioid Receptor Agonist Sales by Application (2020 VS 2024 VS 2031)
5.2.2 Global Opioid Receptor Agonist Sales by Application (2020-2031)
5.2.3 Global Opioid Receptor Agonist Sales Market Share by Application (2020-2031)
5.3 Global Opioid Receptor Agonist Revenue by Application
5.3.1 Global Opioid Receptor Agonist Revenue by Application (2020 VS 2024 VS 2031)
5.3.2 Global Opioid Receptor Agonist Revenue by Application (2020-2031)
5.3.3 Global Opioid Receptor Agonist Revenue Market Share by Application (2020-2031)
6 Global Opioid Receptor Agonist Sales by Region
6.1 Global Opioid Receptor Agonist Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Opioid Receptor Agonist Sales by Region (2020-2031)
6.2.1 Global Opioid Receptor Agonist Sales by Region (2020-2025)
6.2.2 Global Opioid Receptor Agonist Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Opioid Receptor Agonist Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.3.2 North America Opioid Receptor Agonist Sales by Country (2020-2031)
6.3.3 U.S.
6.3.4 Canada
6.3.5 Mexico
6.4 Europe
6.4.1 Europe Opioid Receptor Agonist Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.4.2 Europe Opioid Receptor Agonist Sales by Country (2020-2031)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Opioid Receptor Agonist Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.5.2 Asia Pacific Opioid Receptor Agonist Sales by Country (2020-2031)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 South America, Middle East and Africa
6.6.1 South America, Middle East and Africa Opioid Receptor Agonist Sales Growth Rate by Country: 2020 VS 2024 VS 2031
6.6.2 South America, Middle East and Africa Opioid Receptor Agonist Sales by Country (2020-2031)
6.6.3 Brazil
6.6.4 South Africa
6.6.5 Saudi Arabia
6.6.6 Turkey
6.6.6 Argentina
6.6.6 UAE
6.6.6 Egypt
6.6.6 Chile
7 Global Opioid Receptor Agonist Revenue by Region
7.1 Global Opioid Receptor Agonist Revenue by Region
7.1.1 Global Opioid Receptor Agonist Revenue by Region: 2020 VS 2024 VS 2031
7.1.2 Global Opioid Receptor Agonist Revenue by Region (2020-2025)
7.1.3 Global Opioid Receptor Agonist Revenue by Region (2026-2031)
7.1.4 Global Opioid Receptor Agonist Revenue Market Share by Region (2020-2031)
7.2 North America
7.2.1 North America Opioid Receptor Agonist Revenue (2020-2031)
7.2.2 North America Opioid Receptor Agonist Revenue Share by Country: 2020 VS 2024 VS 2031
7.3 Europe
7.3.1 Europe Opioid Receptor Agonist Revenue (2020-2031)
7.3.2 Europe Opioid Receptor Agonist Revenue Share by Country: 2020 VS 2024 VS 2031
7.4 Asia-Pacific
7.4.1 Asia-Pacific Opioid Receptor Agonist Revenue (2020-2031)
7.4.2 Asia-Pacific Opioid Receptor Agonist Revenue Share by Country: 2020 VS 2024 VS 2031
7.5 South America, Middle East and Africa
7.5.1 South America, Middle East and Africa Opioid Receptor Agonist Revenue (2020-2031)
7.5.2 South America, Middle East and Africa Opioid Receptor Agonist Revenue Share by Country: 2020 VS 2024 VS 2031
8 Company Profiles
8.1 Allergan
8.1.1 Allergan Comapny Information
8.1.2 Allergan Business Overview
8.1.3 Allergan Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.1.4 Allergan Opioid Receptor Agonist Product Portfolio
8.1.5 Allergan Recent Developments
8.2 DAIICHI SANKYO COMPANY
8.2.1 DAIICHI SANKYO COMPANY Comapny Information
8.2.2 DAIICHI SANKYO COMPANY Business Overview
8.2.3 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.2.4 DAIICHI SANKYO COMPANY Opioid Receptor Agonist Product Portfolio
8.2.5 DAIICHI SANKYO COMPANY Recent Developments
8.3 Endo Pharmaceuticals
8.3.1 Endo Pharmaceuticals Comapny Information
8.3.2 Endo Pharmaceuticals Business Overview
8.3.3 Endo Pharmaceuticals Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.3.4 Endo Pharmaceuticals Opioid Receptor Agonist Product Portfolio
8.3.5 Endo Pharmaceuticals Recent Developments
8.4 Fresenius Kabi
8.4.1 Fresenius Kabi Comapny Information
8.4.2 Fresenius Kabi Business Overview
8.4.3 Fresenius Kabi Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.4.4 Fresenius Kabi Opioid Receptor Agonist Product Portfolio
8.4.5 Fresenius Kabi Recent Developments
8.5 Hikma Pharmaceuticals
8.5.1 Hikma Pharmaceuticals Comapny Information
8.5.2 Hikma Pharmaceuticals Business Overview
8.5.3 Hikma Pharmaceuticals Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.5.4 Hikma Pharmaceuticals Opioid Receptor Agonist Product Portfolio
8.5.5 Hikma Pharmaceuticals Recent Developments
8.6 Indivior
8.6.1 Indivior Comapny Information
8.6.2 Indivior Business Overview
8.6.3 Indivior Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.6.4 Indivior Opioid Receptor Agonist Product Portfolio
8.6.5 Indivior Recent Developments
8.7 Mylan N.V.
8.7.1 Mylan N.V. Comapny Information
8.7.2 Mylan N.V. Business Overview
8.7.3 Mylan N.V. Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.7.4 Mylan N.V. Opioid Receptor Agonist Product Portfolio
8.7.5 Mylan N.V. Recent Developments
8.8 Piramal Critical Care
8.8.1 Piramal Critical Care Comapny Information
8.8.2 Piramal Critical Care Business Overview
8.8.3 Piramal Critical Care Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.8.4 Piramal Critical Care Opioid Receptor Agonist Product Portfolio
8.8.5 Piramal Critical Care Recent Developments
8.9 Purdue Pharma
8.9.1 Purdue Pharma Comapny Information
8.9.2 Purdue Pharma Business Overview
8.9.3 Purdue Pharma Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.9.4 Purdue Pharma Opioid Receptor Agonist Product Portfolio
8.9.5 Purdue Pharma Recent Developments
8.10 Sun Pharmaceutical Industries
8.10.1 Sun Pharmaceutical Industries Comapny Information
8.10.2 Sun Pharmaceutical Industries Business Overview
8.10.3 Sun Pharmaceutical Industries Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.10.4 Sun Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
8.10.5 Sun Pharmaceutical Industries Recent Developments
8.11 Tris Pharma
8.11.1 Tris Pharma Comapny Information
8.11.2 Tris Pharma Business Overview
8.11.3 Tris Pharma Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.11.4 Tris Pharma Opioid Receptor Agonist Product Portfolio
8.11.5 Tris Pharma Recent Developments
8.12 US WorldMeds
8.12.1 US WorldMeds Comapny Information
8.12.2 US WorldMeds Business Overview
8.12.3 US WorldMeds Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.12.4 US WorldMeds Opioid Receptor Agonist Product Portfolio
8.12.5 US WorldMeds Recent Developments
8.13 Pfizer
8.13.1 Pfizer Comapny Information
8.13.2 Pfizer Business Overview
8.13.3 Pfizer Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.13.4 Pfizer Opioid Receptor Agonist Product Portfolio
8.13.5 Pfizer Recent Developments
8.14 Johnson & Johnson
8.14.1 Johnson & Johnson Comapny Information
8.14.2 Johnson & Johnson Business Overview
8.14.3 Johnson & Johnson Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.14.4 Johnson & Johnson Opioid Receptor Agonist Product Portfolio
8.14.5 Johnson & Johnson Recent Developments
8.15 Teva Pharmaceutical Industries
8.15.1 Teva Pharmaceutical Industries Comapny Information
8.15.2 Teva Pharmaceutical Industries Business Overview
8.15.3 Teva Pharmaceutical Industries Opioid Receptor Agonist Sales, Price, Revenue and Gross Margin (2020-2025)
8.15.4 Teva Pharmaceutical Industries Opioid Receptor Agonist Product Portfolio
8.15.5 Teva Pharmaceutical Industries Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Opioid Receptor Agonist Value Chain Analysis
9.1.1 Opioid Receptor Agonist Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Opioid Receptor Agonist Production Mode & Process
9.2 Opioid Receptor Agonist Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Opioid Receptor Agonist Distributors
9.2.3 Opioid Receptor Agonist Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.